Skip to content
Research Article Open access CC BY 4.0

Effects of Liraglutide 3.0 mg Injection on Weight Reduction and Metabolic Parameters for Patients Living with Obesity and Type 2 Diabetes Mellitus

Hanadi Alnageeb, Aseilah Al Qaidy, Ashraf ALakkad, Rania Murad, Ibrahim Mahgoub, Masah Mardini, Mahgoub , Ibrahim, Heba Shalabi, Ahmad Mhd Asim Rabih, Aji Gopakumar, Murad , Rania, Rabih, Ahmad Mhd Asim

Advances in Research · pp. 28–45 · Published 18 Feb 2023

10.9734/air/2023/v24i2936

Abstract

Background: By 2025, it is projected that one billion adults will be classified as having obesity worldwide. Unfortunately, the disease of obesity remains vastly undertreated. As an example, in the United States, nearly half of the adults meet recommendations for anti-obesity pharmacotherapy (defined as having a BMI ≥ 30, or a BMI ≥ 27 with weight-related diseases). Owing to its impact on weight loss, remission of diabetes mellitus, and metabolic syndrome, treatment of obesity with medical therapy like Liraglutide 3.0 mg injection has offered hope for obese individuals. In recent years, obesity has increased in the UAE and the use of medical treatment for obesity has increased in-line with this trend. However, data regarding medical treatment for obesity outcomes in diabetic and non-diabetic Emirati people is scarce. Objectives:  The primary objective of the study is to evaluate the effect of Liraglutide 3.0 mg injection for weight management in patients with diabetes mellitus. In addition, we evaluated the impact of weight reduction in improving the metabolic parameters (HbA1c and LDL-c for a patient living with type2 diabetes). Secondary objectives include improvement of infertility in females with PCOS and improvement of psychological well-being, functional capacity and quality of life. Also, we evaluated the response post-bariatric group who received Liraglutide 3.0 mg to treat their post-bariatric weight regain. Results: In terms of weight changes, the average weight at baseline was 100.98 kg and had decreased to 97.54 kg, 96.00 kg, and 96.37 kg at 3, 6, and 12 months, respectively. Males experienced a greater rate of weight reduction than females, while diabetic patients had a lower percentage of weight loss than non-diabetic patients. Additionally, patients with PCOS were able to conceive after reducing 10% of their body weight after using Liraglutide, while the remaining 15 patients who were married but unable to conceive had an improvement in their menstrual cycle and hirsutism. Conclusion: The results demonstrated that Liraglutide helps to induce and sustain weight loss in patients with obesity. It is an effective treatment for weight reduction and offers the unique benefit of improved glycaemic control. In addition, the study identified a correlation between weight reduction and improvements in psychological health, quality of life, and fertility in females with PCOS. Additional studies are needed to determine its long-term efficacy and safety profile.

Type 2 diabetes body mass index (BMI) polycystic ovarian syndrome (PCOS)

References (14)

  1. 1 Lifestyle modification approaches for the treatment of obesity in adults. [DOI]
  2. 2 Liraglutide for weight management: a critical review of the evidence [DOI]
  3. 3 Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial [DOI]
  4. 4 Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome [DOI]
  5. 5 Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes [DOI]
  6. 6 Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes [DOI]
  7. 7 Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients [DOI]
  8. 8 Correlation Between Baseline Characteristics and Clinical Outcomes in a Large Population of Diabetes Patients Treated with Liraglutide in a Real-World Setting in Italy [DOI]
  9. 9 Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study [DOI]
  10. 10 Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study [DOI]
  11. 11 Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial [DOI]
  12. 12 Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy [DOI]
  13. 13 Understanding the Gaps in Obesity Management in the UAE: Perceptions, Barriers, and Attitudes [DOI]
  14. 14 Liraglutide Effect on Blood Pressure, Lipids Profile, and Liver Enzymes in Arab Patients with Type 2 Diabetes Mellitus: A Prospective LIRA-BPL Study [DOI]

Cited by 2

Metabolic resilience: liraglutide’s potential in alleviating depressive symptoms

Omar Gammoh, Esam Qnais, Alaa A. A. Aljabali · Molecular Biology Reports · 2025

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

75

Page views

0

PDF downloads

28

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.